Mark Schiffman Selected Research

Squamous Intraepithelial Lesions

10/2020	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers.
12/2016	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
11/2015	Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.
10/2015	The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy.
7/2007	Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type.
1/2006	Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).
7/2005	Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
8/2004	Interlaboratory reliability of Hybrid Capture 2.
6/2003	Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy.
6/2003	Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Schiffman Research Topics

Disease

56	Neoplasms (Cancer) 01/2022 - 04/2002
51	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/2021 - 09/2002
46	Infections 01/2021 - 03/2002
44	Papillomavirus Infections 01/2021 - 09/2002
34	Uterine Cervical Dysplasia 01/2022 - 09/2002
21	Atypical Squamous Cells of the Cervix 01/2022 - 01/2002
11	Squamous Intraepithelial Lesions 10/2020 - 01/2002
5	Carcinogenesis 12/2021 - 02/2013
4	Carcinoma (Carcinomatosis) 10/2005 - 11/2002
3	Persistent Infection 01/2016 - 10/2011
2	Papilloma (Papillomatosis) 01/2020 - 09/2014
2	Spontaneous Abortion (Miscarriage) 09/2015 - 03/2010
2	Inflammation (Inflammations) 01/2014 - 05/2008
2	Coinfection 04/2011 - 09/2009
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 05/2008 - 07/2003
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022
1	Uterine Prolapse (Vaginal Prolapse) 04/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2017
1	Squamous Cell Carcinoma of Head and Neck 09/2013
1	Hepatitis A (Hepatitis, Infectious) 09/2013
1	Intellectual Disability (Idiocy) 04/2013
1	Brain Neoplasms (Brain Tumor) 04/2013
1	alpha-Thalassemia 04/2013
1	Melanoma (Melanoma, Malignant) 04/2013
1	Adenocarcinoma in Situ 04/2013
1	Oropharyngeal Neoplasms 01/2013
1	Prostatic Neoplasms (Prostate Cancer) 09/2011
1	Gonorrhea 04/2010
1	Virus Diseases (Viral Diseases) 01/2010
1	Polyps 07/2009
1	Ulcer 07/2009
1	Vulvar Neoplasms (Vulvar Cancer) 08/2008
1	Head and Neck Neoplasms (Head and Neck Cancer) 08/2008
1	Vaginal Neoplasms (Cancer, Vaginal) 08/2008

Drug/Important Bio-Agent (IBA)

55	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2002
42	VaccinesIBA 01/2022 - 02/2004
18	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2003
17	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2022 - 08/2008
11	AntibodiesIBA 10/2020 - 03/2002
7	Acetic Acid (Vinegar)FDA LinkGeneric 06/2021 - 07/2007
6	Oral ContraceptivesIBA 02/2013 - 09/2002
5	Biological ProductsIBA 01/2020 - 10/2005
4	Coloring Agents (Dyes)IBA 01/2021 - 12/2014
4	Combined VaccinesIBA 12/2020 - 03/2010
4	HLA Antigens (Human Leukocyte Antigens)IBA 11/2018 - 04/2002
4	ParaffinIBA 01/2017 - 08/2004
3	Contraceptive Agents (Contraceptives)IBA 01/2021 - 06/2005
3	CytokinesIBA 01/2014 - 05/2003
3	EnzymesIBA 01/2013 - 11/2002
2	Messenger RNA (mRNA)IBA 01/2018 - 06/2015
2	P-2 (P 2)IBA 12/2016 - 04/2013
2	Proteins (Proteins, Gene)FDA Link 06/2015 - 04/2013
2	NucleotidesIBA 10/2014 - 09/2013
2	Viral DNAIBA 12/2012 - 06/2005
2	MitogensIBA 08/2010 - 11/2006
2	AntigensIBA 08/2010 - 11/2006
2	Peptides (Polypeptides)IBA 01/2010 - 07/2003
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018
1	Amino Acids FDA Link 09/2017
1	Formaldehyde (Formol)FDA Link 01/2017
1	Virus-Like Particle VaccinesIBA 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	Hepatitis A Vaccines (Hepatitis A Vaccine)IBA 09/2015
1	Estrogen ReceptorsIBA 06/2015
1	Estrogens (Estrogen)FDA Link 06/2015
1	Interleukin-8 (Interleukin 8)IBA 06/2015
1	Estrogen Receptor alphaIBA 06/2015
1	hydrogen sulfite (bisulfite)IBA 02/2015
1	Glutathione Transferase (Glutathione S-Transferase)IBA 03/2014
1	ChemokinesIBA 01/2014
1	Telomerase (Telomerase Reverse Transcriptase)IBA 04/2013
1	Telomere-Binding ProteinsIBA 04/2013
1	N 30IBA 04/2012
1	CarcinogensIBA 01/2012
1	ribosomal protein S19IBA 01/2012
1	Peroxiredoxin IIIIBA 01/2012
1	Adenosine Triphosphate (ATP)IBA 10/2011
1	ORALIT (ORS)IBA 04/2011
1	Immunologic Factors (Immunomodulators)IBA 12/2010
1	2',5'-Oligoadenylate Synthetase (2',5' Oligoadenylate Synthetase)IBA 01/2010
1	Transcription Factor TFIIHIBA 01/2010
1	SulfatasesIBA 01/2010
1	Interferon-gamma (Interferon, gamma)IBA 01/2010
1	deoxyuridine triphosphateIBA 01/2010
1	Codon (Codons)IBA 05/2009
1	polycyclic aromatic hydrocarbons-DNA adductIBA 11/2007
1	SmokeIBA 11/2007

Therapy/Procedure

3	Conservative Treatment 01/2018 - 01/2006
3	Curettage 12/2017 - 08/2007
3	Aftercare (After-Treatment) 01/2016 - 07/2012
2	Injections 01/2021 - 12/2005
2	Hysterectomy 07/2012 - 06/2005
2	Cryotherapy (Therapy, Cold) 07/2009 - 05/2009
1	Surgical Instruments (Clip) 04/2020
1	Operative Surgical Procedures 01/2020
1	Lasers (Laser) 01/2020
1	Precision Medicine 11/2016
1	Secondary Prevention 10/2008
1	Condoms (Condom) 05/2008
1	Intrauterine Devices (Intrauterine Device) 05/2008